title: Fasting improves discrimination of grade 1 and atypical or malignant meningioma in FDG-PET.
abstract: We investigated the use of PET with 2[18F]fluoro-2-deoxy-D-glucose (FDG) to discriminate between atypical or malignant and grade 1 meningiomas. The influence of fasting state and high-dose corticosteroid medication was analyzed retrospectively.
  
  
  METHODS
  Preoperative PET scans of 75 patients with suspected diagnosis of intracranial meningioma were evaluated using standardized uptake values (SUV) and tumor-to-contralateral gray matter ratios (TGR) of FDG uptake. Fifty-one of 75 patients fasted before the PET scan, and 27 of 75 patients were studied under high-dose corticosteroid medication. Eighteen tumors had recurred. PET results were compared to histopathological grading.
  
  
  RESULTS
  PET correctly identified 8/9 atypical or malignant meningiomas and 58/66 grade 1 meningiomas using TGR and a threshold of 1.05 in primary meningioma and 0.85 in tumor recurrence. This corresponds to a specificity of 0.88 for the detection of higher tumor grading. Specificity was significantly higher in fasting compared to nonfasting subjects (0.96 versus 0.73; p < 0.025). SUV quantification lead to a reduced specificity of 0.77 at the same level of sensitivity. The only false-negative PET finding occurred in a recurrent meningioma, which had been operated on four times before.
  
  
  CONCLUSIONS
  Overnight fasting before injection is needed to improve the diagnostic accuracy of FDG-PET for noninvasive metabolic grading of meningioma. Hyperglycemia in nonfasting patients and in diabetic patients may lead to overestimation of meningioma grading.
authors.affiliation: Department of Nuclear Medicine, Aachen University of Technology, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Cremerius
authors.forename: R
authors.initials: R
authors.lastname: Bares
authors.forename: J
authors.initials: J
authors.lastname: Weis
authors.forename: O
authors.initials: O
authors.lastname: Sabri
authors.forename: M
authors.initials: M
authors.lastname: Mull
authors.forename: J M
authors.initials: JM
authors.lastname: Schröder
authors.forename: J M
authors.initials: JM
authors.lastname: Gilsbach
authors.forename: U
authors.initials: U
authors.lastname: Buell
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003847:Deoxyglucose / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D003937:Diagnosis, Differential; D005215:Fasting / Q000502:physiology*; D005260:Female; D005462:Fluorine Radioisotopes / Q000493:pharmacokinetics; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008577:Meningeal Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism; D008579:Meningioma / Q000000981:diagnostic imaging* / Q000378:metabolism; D008875:Middle Aged; D012189:Retrospective Studies; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed
chemical_list: D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D003847:Deoxyglucose